Literature DB >> 22974965

Living donor psychosocial assesment/follow-up practices in the partners' countries of the ELIPSY project.

M Manyalich1, A Menjívar, L Yucetin, J M Peri, X Torres, L Dias, C Hiesse, C Papachristou, I Fehrman-Ekholm, N Kvarnström, C Ballesté, D Paredes, I Revuelta, F Diekmann, A Rimola, C Fondevila, M Martínez, C Legendre, R C Pereira, I A Carvalho, A Lopes.   

Abstract

BACKGROUND: Living donor (LD) transplantation has increased recently, but psychosocial aspects of living donation have not been well characterized, as risk factors for the donors. ELIPSY is a project confunded by EAHC, seeking to develop a common methodology for all EU countries for LD assessment/follow-up in the psychosocial sphere (www.eulivingdonor.eu).
OBJECTIVE: To evaluate current psychosocial LD assessment/follow-up practices among European centers for key aspects and differences between kidney and liver programs.
METHODS: Within a timeline of 30 months, this phase of the project sought to identify current LD psychosocial assessment/follow-up practices. The final survey concerned two versions focused on the kidney and on liver transplant program. The survey took place in ELIPSY partner centers under their own responsibility. Each of the centers sent the survey to other ones performing LD in their country. Partners in the EULID project includes ones in the United Kingdom, Poland, and Romania. The results were analyzed separately for each program seeking to compare and define differences among them.
RESULTS: The survey took place in 10 European countries including 65 centers with LD programs. Positive answers regarding psychosocial assessment/follow-up practices were obtained for 26 (42%) kidney and nine (38%) liver centers. Some centers perform several psychosocial follow-ups but did not explain their tools, whereas the centers that did explain the tools used the same ones for both programs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22974965     DOI: 10.1016/j.transproceed.2012.07.106

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.

Authors:  Krista L Lentine; Bertram L Kasiske; Andrew S Levey; Patricia L Adams; Josefina Alberú; Mohamed A Bakr; Lorenzo Gallon; Catherine A Garvey; Sandeep Guleria; Philip Kam-Tao Li; Dorry L Segev; Sandra J Taler; Kazunari Tanabe; Linda Wright; Martin G Zeier; Michael Cheung; Amit X Garg
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

2.  Evaluation of Psychosocial Outcomes of Living Liver Donors in Liver Transplantation.

Authors:  Yaprak Sarıgöl Ordin; Arzu Kader Harmancı Seren; Özgül Karayurt; Gülay Aksu Kul; Murat Kılıç; Cemal Ata Bozoklar; Yaman Tokat
Journal:  Turk J Gastroenterol       Date:  2022-04       Impact factor: 1.555

3.  Managing the Psychosocial and Financial Consequences of Living Donation.

Authors:  Mary Amanda Dew; Larissa Myaskovsky; Jennifer L Steel; Andrea F DiMartini
Journal:  Curr Transplant Rep       Date:  2014-03-01

4.  Living kidney donor and recipient perspectives on their relationship: longitudinal semi-structured interviews.

Authors:  Angelique F Ralph; Phyllis Butow; Jonathan C Craig; Germaine Wong; Steve J Chadban; Grant Luxton; Talia Gutman; Camilla S Hanson; Angela Ju; Allison Tong
Journal:  BMJ Open       Date:  2019-04-04       Impact factor: 2.692

5.  Psychosocial risk factors for impaired health-related quality of life in living kidney donors: results from the ELIPSY prospective study.

Authors:  Ana Menjivar; Xavier Torres; Marti Manyalich; Ingela Fehrman-Ekholm; Christina Papachristou; Erika de Sousa-Amorim; David Paredes; Christian Hiesse; Levent Yucetin; Federico Oppenheimer; Entela Kondi; Josep Maria Peri; Niclas Kvarnström; Chloë Ballesté; Leonidio Dias; Inês C Frade; Alice Lopes; Fritz Diekmann; Ignacio Revuelta
Journal:  Sci Rep       Date:  2020-12-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.